ZIP (SCRAMBLED) (Synonyms: z-Pseudosubstrate inhibitory peptide) |
| Catalog No.GC13461 |
PKMζ inhibitor
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 908012-18-0
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
IC50: By suppressing protein kinase Mξ (PKMξ), ZIP reverses late-phase LTP with an IC50 of 1 - 2.5 μM.
Long-term potentiation (LTP), a persistent synaptic enhancement, is considered to be a substrate for memory. A typical LTP process includes two phases, induction and maintenance. PKMξ as an active form of protein kinase C (PKC) isozyme is necessary and potent for LTP maintenance. ZIP is applied as a novel and cell-permeable inhibitor for PKMξ and can therefore block LTP. [1]
In vitro: In order to determine the specific phase of LTP affected by PKMξ, ZIP was added at different concentrations to the bath before cells incubation. Experiments with ZIP were compared with experiments without the peptide. This study showed that ZIP could selectively inhibit PKMξ-induced synaptic potentiation in hippocampal slices in vitro. [2]
In vivo: ZIP was the first tool available to test the maintenance hypothesis in vitro. The effect of ZIP on late phase of LTP in vivo was also detected using the rat hippocampus. It was found that intra-hippocampal injection of ZIP with a dosage of 10 nmol in 1 ml saline rapidly reversed the late-phase LTP and led to persistent loss of 1-day-old spatial memory. [3]
Clinical trial: So far, no clinical trial has been conducted.
References:
[1]Ling SF, Benardo LS, Serrano PA, Blace N, Kelly MT, Crary JF and Sacktor TC. Protein kinase Mξ is necessary and sufficient for LTP maintenance. Nat. Neurosci. 2002 Apr. 5(4): 2956.
[2]Serrano P, Yao Y and Sacktor TC. Persistent phosphorylation by protein kinase maintains late-phase long-term potentiation. J. Neurosci. 2005 Feb. 25(8): 1979–84.
[3]Pastalkova E, Serrano P, Pinkhasova D, Wallace E, Fenton AA, Sacktor TC. Storage of spatial information by the maintenance mechanism of LTP. Science. 2006 Aug. 313: 1141-4.
| Cas No. | 908012-18-0 | SDF | |
| Synonyms | z-Pseudosubstrate inhibitory peptide | ||
| Formula | C90H154N30O17 | M.Wt | 1928.4 |
| Solubility | ≥ 192.8mg/mL in DMSO | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 518.6 μL | 2.5928 mL | 5.1856 mL |
| 5 mM | 103.7 μL | 518.6 μL | 1.0371 mL |
| 10 mM | 51.9 μL | 259.3 μL | 518.6 μL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 18 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *